Tables
- TABLE 1
Baseline characteristics
Category Radiation therapy group Non-radiation therapy group p-value Patients n 23 23 Age at diagnosis years 63 (41–77) 62 (43–79) 0.26 Females 13 (57) 15 (65.1) 0.14 Smoking history 18 (90) 19 (95) 0.26 Smoking pack-years 43.2±23.4 44.5±21.6 0.85 Body mass index kg·m−2 25.6±4.9 25.8±5.4 0.86 Serum LDH U·L−1 264.8±64.4 380.5±80.1 0.08 FEV1 % pred 76.75±24.4 61.4±27.9 0.10 FVC % 87.4±21.3 92.5±12.5 0.72 Lung disease on CT scan 0.89 Emphysema 14 (60.9) 12 (52.2) Interstitial lung disease 2 (8.7) 1 (4.3) Bronchiectasis 0 0 Histology of tumour Adenocarcinoma 16 (69.6) 16 (69.6) Squamous cell carcinoma 7 (30.4) 7 (30.4) Stage at the time of inclusion# 0.75 Stage IV 19 (82.6) 21 (91.3) Stage IIIB 4 (17.4) 2 (8.7) Previous chemotherapy cycles 6 (1–18) 4 (2–10) 0.11 Lines of chemotherapy prior to nivolumab 1 (1–3) 1 (1–3) Previous chemotherapy 0.59 Carboplatin 22 (95.7) 22 (95.7) Cisplatin 1 (4.4) 1 (4.4) Gemcitabine 12 (52.2) 19 (82.6) Paclitaxel 14 (90.9) 4 (17.4) Vinorelbine 1 (4.4) 1 (4.4) Pemetrexed 2 (8.7) 3 (13.0) Previous radiation therapy Thoracic 23 (100) Extrathoracic 4 (17.4) Previous radiation therapy intent Previous definitive concurrent chemoradiation 18 (78.3) Previous palliative radiotherapy 5 (21.7) ECOG score at the start of nivolumab 2 (1–2) 2 (1–2) Nivolumab cycles 9 (1–47)* 5 (1–34)* 0.01 Data are presented as median (range), mean±sd or n (%), unless otherwise stated. LDH: lactate dehydrogenase; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; CT: computed tomography; ECOG: Eastern Cooperative Oncology Group performance status score. #: stage of non-small cell lung cancer prior to initiation of nivolumab was based on the seventh Tumour, Node, Metastasis classification of lung cancer. *: p<0.05.
Vol 6 Issue 1
Table of Contents
Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study
